Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas

  title={Good things come in small packages: low-dose radiation as palliation for indolent non-Hodgkin lymphomas},
  author={Neil E. Martin and Andrea K. Ng},
  journal={Leukemia \& Lymphoma},
  pages={1765 - 1772}
Numerous management options are available to patients with advanced-stage or relapsed/refractory indolent non-Hodgkin lymphomas (NHLs). These include observation in patients with low-volume disease, systemic therapy including radioimmunotherapy, and high-dose therapy with stem cell transplant. In selected patients with localized symptomatic disease, local radiation therapy to sites of involvement can offer effective palliation. However, systemic therapy and standard-dose radiation therapy can… 

Palliation by low-dose local radiation therapy for indolent non-Hodgkin lymphoma.

  • E. ChanS. Fung R. Tsang
  • Medicine
    International journal of radiation oncology, biology, physics
  • 2011

Hematologic Malignancies.

  • Y. TsengA. Ng
  • Medicine
    Hematology/oncology clinics of North America
  • 2020
Reducing radiation doses and treatment volume in selected cases, and the use of advanced radiotherapy technology, can improve the therapeutic ratio of patients receiving radiation therapy for hematologic malignancies.

Enhancement of T Cell Responses as a Result of Synergy between Lower Doses of Radiation and T Cell Stimulation

Enhanced T cell function induced by synergistic radiation treatment is reported, with potential physiological significance in a wide range of T cell responses.

The levels of Serum Alkaline Phosphatase and Lactate Dehydrogenase in Hodgkin Lymphoma

Lactate Dehydrogenase and Alkaline Phosphatase levels might be utilized as markers to determine Hodgkin's lymphoma severity in addition to other markers.

The Rich Picture



Low dose palliative radiotherapy in low grade non-Hodgkin's lymphoma.

  • E. J. SawyerA. Timothy
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 1997

Value of low-dose 2 x 2 Gy palliative radiotherapy in advanced low-grade non-Hodgkin's lymphoma.

Early experience using low-dose radiotherapy for patients with advanced-stage follicular, mucosal associated lymphoid tissue, mantle cell and small lymphocytic lymphomas finds response rates were high, the response durable and the toxicity was minimal.

High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.

  • R. HaasP. Poortmans H. Bartelink
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
LD-IF-RT is a valuable asset in the management of patients with follicular lymphoma and should be considered in patients with recurrent disease, and none of the factors studied were found to be related to response rate.

Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas.

Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.

  • S. LuthyA. Ng P. Mauch
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2008
LD-IF-RT for selected NHL subtypes has excellent local CR and in-field control rates and may postpone the need for systemic therapy.

Long-term results of low dose total body irradiation for advanced non-Hodgkin lymphoma.

Low dose fractionated whole body irradiation in the treatment of advanced non‐Hodgkin's lymphoma

Fractionated whole body irradiation is an excellent systemic induction agent for advanced lymphocytic and mixed lymphoma and response rate, response duration, and median nadir platelet or WBC counts between the two schedules are demonstrated.

Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B.

  • B. PetersonG. Petroni A. Gottlieb
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2003
There is no advantage to the initial use of the relatively intensive combination, CHOP-B, for patients with FSCL compared with the less toxic single agent, cyclophosphamide, but in an unplanned subgroup analysis, patients with FML who received the combination experienced improved disease control and survival.